These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1354 related articles for article (PubMed ID: 16921036)

  • 21. [Treatment of soft tissue sarcomas in childhood and adolescence: results of the CWS-81 multicenter therapy study].
    Koscielniak E; Treuner J; Jürgens H; Winkler K; Bürger D; Herbst M; Ritter J; Niethammer D; Müller-Weihrich S; Bernhard G
    Klin Padiatr; 1991; 203(4):211-9. PubMed ID: 1942928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997.
    Raney RB; Stoner JA; Walterhouse DO; Andrassy RJ; Donaldson SS; Laurie F; Meyer WH; Qualman SJ; Crist WM;
    Pediatr Blood Cancer; 2004 Jun; 42(7):618-25. PubMed ID: 15127417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee.
    Rodeberg DA; Anderson JR; Arndt CA; Ferrer FA; Raney RB; Jenney ME; Brecht IB; Koscielniak E; Carli M; Bisogno G; Oberlin O; Rey A; Ullrich F; Stevens MC; Meyer WH
    Int J Cancer; 2011 Mar; 128(5):1232-9. PubMed ID: 20473932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the third Intergroup Rhabdomyosarcoma Study.
    Wharam MD; Meza J; Anderson J; Breneman JC; Donaldson SS; Fitzgerald TJ; Michalski J; Teot LA; Wiener ES; Meyer WH
    J Clin Oncol; 2004 May; 22(10):1902-8. PubMed ID: 15143083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    ; Lager JJ; Lyden ER; Anderson JR; Pappo AS; Meyer WH; Breitfeld PP
    J Clin Oncol; 2006 Jul; 24(21):3415-22. PubMed ID: 16849756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
    J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Rhabdomyosarcoma: therapeutic results and prospectives].
    Guglielmi M; Carli M
    Pediatr Med Chir; 1984; 6(2):179-84. PubMed ID: 6549408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
    Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III.
    Wolden SL; Anderson JR; Crist WM; Breneman JC; Wharam MD; Wiener ES; Qualman SJ; Donaldson SS
    J Clin Oncol; 1999 Nov; 17(11):3468-75. PubMed ID: 10550144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan AA; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
    J Clin Oncol; 2014 Nov; 32(31):3547-52. PubMed ID: 25267746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
    Miser JS; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Grier HE
    J Clin Oncol; 2004 Jul; 22(14):2873-6. PubMed ID: 15254055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroblastoma.
    Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M
    Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of intensified chemotherapy in children with advanced rhabdomyosarcoma (clinical groups III and IV). The Intergroup Rhabdomyosarcoma Study (IRS) Committee of the Cancer and Leukemia Group B Children's Cancer Study Group, Southwest Oncology Group.
    Raney RB; Gehan EA; Maurer HM; Newton WA; Ragab AH; Ruymann FB; Sutow WW; Tefft M
    Cancer Clin Trials; 1979; 2(1):19-28. PubMed ID: 391431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
    Pappo AS; Devidas M; Jenkins J; Rao B; Marcus R; Thomas P; Gebhardt M; Pratt C; Grier HE
    J Clin Oncol; 2005 Jun; 23(18):4031-8. PubMed ID: 15767644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.
    Breneman JC; Lyden E; Pappo AS; Link MP; Anderson JR; Parham DM; Qualman SJ; Wharam MD; Donaldson SS; Maurer HM; Meyer WH; Baker KS; Paidas CN; Crist WM
    J Clin Oncol; 2003 Jan; 21(1):78-84. PubMed ID: 12506174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial.
    Klingebiel T; Boos J; Beske F; Hallmen E; Int-Veen C; Dantonello T; Treuner J; Gadner H; Marky I; Kazanowska B; Koscielniak E
    Pediatr Blood Cancer; 2008 Apr; 50(4):739-45. PubMed ID: 18286501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Third Intergroup Rhabdomyosarcoma Study.
    Crist W; Gehan EA; Ragab AH; Dickman PS; Donaldson SS; Fryer C; Hammond D; Hays DM; Herrmann J; Heyn R
    J Clin Oncol; 1995 Mar; 13(3):610-30. PubMed ID: 7884423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
    Spunt SL; Smith LM; Ruymann FB; Qualman SJ; Donaldson SS; Rodeberg DA; Anderson JR; Crist WM; Link MP
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6072-9. PubMed ID: 15447992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
    J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Definitive surgery and multiagent systemic therapy for patients with localized Ewing sarcoma family of tumors: local outcome and prognostic factors.
    Krasin MJ; Davidoff AM; Rodriguez-Galindo C; Billups CA; Fuller CE; Neel MD; Merchant TE
    Cancer; 2005 Jul; 104(2):367-73. PubMed ID: 15948159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.